Skip to main content
. 2001 Oct 9;98(21):12197–12202. doi: 10.1073/pnas.211442598

Figure 4.

Figure 4

Pituitary LHRH-R mRNA expression and serum LH in OVX rats during and after the treatment for 10 days with a depot formulation of cetrorelix pamoate, releasing 100 μg/day or repeated daily injection of 100 μg of triptorelin. (a) LHRH-R mRNA level. (b) RT-PCR products of the pituitary LHRH-R mRNA and β-actin mRNA after separation by agarose gel electrophoresis and staining with ethidium bromide. M, 100-bp DNA molecular weight marker; lanes 1–3, cetrorelix-treated; lanes 4–6, triptorelin-treated; lanes 7–9, untreated control. (c) Serum LH during the treatment. **, P < 0.01 vs. control or 0 h; +, P < 0.05; ++, P < 0.01 vs. corresponding value on day 1; Tripto, triptorelin; Cetro, cetrorelix.